Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Galapagos NV (GLPG)

40.24   -0.44 (-1.08%) 11-28 16:00
Open: 40.95 Pre. Close: 40.68
High: 41.3 Low: 40.09
Volume: 110,024 Market Cap: 2,649(M)

Technical analysis

as of: 2022-11-28 4:40:11 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 51.62     One year: 54.86
Support: Support1: 39.7    Support2: 33.03
Resistance: Resistance1: 44.19    Resistance2: 46.97
Pivot: 41.02
Moving Average: MA(5): 40.54     MA(20): 42.06
MA(100): 47.71     MA(250): 54.58
MACD: MACD(12,26): -1.1     Signal(9): -1
Stochastic oscillator: %K(14,3): 17     %D(3): 14.5
RSI: RSI(14): 35.6
52-week: High: 72.11  Low: 39.7
Average Vol(K): 3-Month: 162 (K)  10-Days: 94 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GLPG ] has closed above bottom band by 13.3%. Bollinger Bands are 64.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 41.32 - 41.6 41.6 - 41.83
Low: 39.56 - 39.83 39.83 - 40.05
Close: 39.85 - 40.28 40.28 - 40.64

Company Description

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Headline News

Sat, 26 Nov 2022
Galapagos NV (NASDAQ:GLPG) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Wed, 16 Nov 2022
Galapagos ADR Representing Ord Shs (GLPG) Stock: Do Analysts Think You Should Sell? - InvestorsObserver

Sat, 12 Nov 2022
Galapagos (NASDAQ:GLPG) Given New €40.00 Price Target at Deutsche Bank Aktiengesellschaft - MarketBeat

Fri, 11 Nov 2022
Galapagos (GLPG) announces CHMP adoption of PRAC's recommendation for Jyseleca® following extensive safety review of all JAK inhibitors -

Tue, 08 Nov 2022
Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022 -

Mon, 07 Nov 2022
Galapagos downgraded to market perform at Raymond James on unclear path forward (GLPG) - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Outperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 66 (M)
Shares Float 41 (M)
% Held by Insiders 0.1 (%)
% Held by Institutions 19.6 (%)
Shares Short 693 (K)
Shares Short P.Month 629 (K)

Stock Financials

EPS 0.09
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 40.86
Profit Margin (%) 0.9
Operating Margin (%) -15.4
Return on Assets (ttm) -1.1
Return on Equity (ttm) 0.2
Qtrly Rev. Growth 112.1
Gross Profit (p.s.) -0.13
Sales Per Share 8.76
EBITDA (p.s.) -0.6
Qtrly Earnings Growth 0
Operating Cash Flow -484 (M)
Levered Free Cash Flow 8 (M)

Stock Valuations

PE Ratio 447.11
PEG Ratio -42.6
Price to Book value 0.98
Price to Sales 4.59
Price to Cash Flow -5.47

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.